Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03949881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency

Study acronym: FEMJA
StatusRecruiting
PhasePhase 1/2
Started2020-11-13
View on ClinicalTrials.gov ↗

Amendment history

2025-12-15
minor
Study Status v9
Primary completion date2029-05-13→2031-05-13
Completion date2029-05-13→2031-05-13
2025-03-10
minor
Study Status v8
Primary completion date2028-05-13→2029-05-13
Completion date2028-05-13→2029-05-13
2024-05-07
minor
Study Status v7
Re-verified, no change to tracked fields
2023-04-21
minor
Study Status v6
Primary completion date2026-05-13→2028-05-13
Completion date2026-05-13→2028-05-13
2022-01-26
minor
Study Status, Eligibility v5
Primary completion date2025-05-13→2026-05-13
Completion date2025-05-13→2026-05-13
Eligibility criteria-39 characters
[...] ation by the investigator and on the following paraclinical parametersparameter: Erythrocyte Sedimentation Rate (ERS), C Reactive Protein rate History of acute phase of ocular in [...]
Show 4 earlier versions
2021-06-02
minor
Study Status v4
Re-verified, no change to tracked fields
2020-12-03
minor
Study Status v3
Primary completion date2025-04-01→2025-05-13
Completion date2025-04-01→2025-05-13
Start dateestimated 2020-10-01→confirmed 2020-11-13
2020-09-17
minor
Study Status, Conditions, Outcome Measures, Eligibility v2
Primary completion date2025-03-01→2025-04-01
Completion date2025-03-01→2025-04-01
Start date2020-09-01→2020-10-01
Eligibility criteria+1 characters
[...] articipation in the study in the opinion of the investigator. Delay of less than one year after chemical or thermal burns [...]
Secondary endpoints+310 characters
Number of successful FEMJA transplantations Number of adverse events related to the procedure Improvement in physical signs Improvement in neovascularization Improvement in symptoms, i.e. functional signs Corneal graft rejection Correlation between biological FEMJA characteristics and changes in vis [...]
2020-08-03
notable
Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-07-01→2025-03-01
Completion date2023-07-01→2025-03-01
Start date2019-12-01→2020-09-01
Eligibility criteria+1,301 characters
Inclusion Criteria: Male or female aged ≥ 18 years Signed and dated informed consent offor participation in the study Total bilateral limbal stem-cell deficiency Caused by thermal or chemical burn, cornea transplantation, and other bilateral disorders of the ocular surface Severe loss of vision (<2/10 on decimal scale or/and EDTRS) The subject must be covered by a social security system Exclusion Criteria- Eye inflammation Strictly unilateral ocular affliction Acute systemic infection:, Consultationobjectified during consultation by physicianthe in serviceinvestigator and decision on the foll [...] [...]
Study sitesdetails revised at 1 of 1 site
2019-05-13
minor
Original filing
Some severe ocular burns or other rare ocular pathologies can be associated with a total loss of corneal epithelial stem cells (i.e. Limbal Stem Cell Deficiency - LSCD), which leads to cornea invasion by the conjunctiva and a subsequent opacification. When LSCD is total and bilateral, both eyes are affected leading to full blindness and a poor quality of life, with a paradoxical photophobia that may be painful. Fewer than 100 patients bear this rare condition in France. When patients suffer from total and bilateral LSCD, no treatment has been proven to provide clinical benefits: contralateral limbus is unavailable for autologous limbus graft or autologous limbal stem cells culture; allogeneic limbus graft requires immunosuppressive treatment leading to too important serious adverse effects compared to the expected benefit, and does not last long (\< 2 years); and allogenic cornea transplantation is impossible since always rejected due to neovascularization. A new way to treat these patients is to cultivate autologous corneal-like epithelium, and to graft it in order to restore transparency and to allow, if needed, a complementary corneal graft. Such an epithelium can be produced from autologous jugal mucosa cells. Epithelial jugal mucosa sheets transplantation has been assessed in a phase I/II clinical trial on 26 patients which showed that it is well-tolerated and effective but the culture technology used in this clinical trial is no longer available. A new enzymatic detachment process has been developed by the Hospices Civils de Lyon. Proof of concept was obtained from both in vitro and ex vivo studies: detachment with Collagenase at 0.5 mg/mL doesn't damage basement membrane proteins, so collagenase 0.5mg/mL-detached FEMJA were found to adhere, continue to ensure renewal of the differentiated epithelium 15 days after grafting onto an ex vivo porcine de-epitheliazed stroma model. Considering these results, we aim to perform a clinical trial in order to evaluate tolerance and efficacy of the autologous jugal mucosa cell sheet (Feuillets Epithéliaux de Muqueuse Jugale Autologue - FEMJA) cultured with this innovative process.
Trial Details
NCT Number NCT03949881
Lead Sponsor Hospices Civils de Lyon
Conditions Total Bilateral Limbal Cell Deficiency
Enrollment 40 participants
Start Date 2020-11-13
Primary Completion 2031-05-13 (estimated)
Study Completion 2031-05-13 (estimated)
Updated on ClinicalTrials.gov 2025-12-16